Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 13/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.79 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18789169 | 0.88 | MKNK2 (1.00) | MKNK2MKNK1IRAK4CYP1A2CYP2C9 | |
| SCHEMBL18789188 | 0.81 | MKNK2 (1.00) | MKNK2MKNK1 | |
| SCHEMBL18789200 | 0.77 | MKNK2 (0.72) | MKNK2MKNK1IRAK4DGAT1PRMT5 | |
| SCHEMBL18789197 | 0.73 | MKNK2 (0.57) | MKNK2MKNK1CYP1A2CYP2C9HSD17B10 | |
| SCHEMBL18789202 | 0.72 | MKNK2 (0.98) | MKNK2MKNK1IRAK4DGAT1 | |
| SCHEMBL18789183 | 0.71 | MKNK2 (1.00) | MKNK2MKNK1DGAT1 | |
| SCHEMBL18814529 | 0.70 | MKNK2 (0.55) | MKNK2MKNK1DGAT1PRMT5WDR77 | |
| SCHEMBL18797874 | 0.69 | MKNK2 (1.00) | MKNK2MKNK1IRAK4 | |
| Hydrochloric Acid SCHEMBL18789216 | 0.68 | MKNK2 (0.98) | MKNK2MKNK1IRAK4 | |
| SCHEMBL18789210 | 0.65 | MKNK2 (1.00) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2017075412-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | MKNK2 37/4885MKNK1 67/4885IRAK4 242/4885 |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | MKNK2 38/4885MKNK1 67/4885IRAK4 244/4885 |
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | NEK9, NEK2, TYK2 | MKNK2 37/4885MKNK1 67/4885IRAK4 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.